a2f13560-4d23-4ef8-8c69-a5b6279d5b21
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- OXIDATIVE_PHOSPHORYLATION+0.480
- MYC_TARGETS_V1+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.460
- MTORC1_SIGNALING+0.410
- DNA_REPAIR+0.400
- CHOLESTEROL_HOMEOSTASIS+0.360
- UV_RESPONSE_UP+0.340
- E2F_TARGETS+0.330
- GLYCOLYSIS+0.320
Top 10 suppressed
- UV_RESPONSE_DN-0.440
- INTERFERON_ALPHA_RESPONSE-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- INTERFERON_GAMMA_RESPONSE-0.300
- ANGIOGENESIS-0.270
- ALLOGRAFT_REJECTION-0.250
- KRAS_SIGNALING_UP-0.240
- TGF_BETA_SIGNALING-0.230
- TNFA_SIGNALING_VIA_NFKB-0.230
- MITOTIC_SPINDLE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475158 | — | — | 0.937 |
| 2 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.877 |
| 3 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.875 |
| 4 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.864 |
| 5 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.861 |
| 6 | f20785b9-991d-4b87-8ba7-ca32373f1996 | — | — | 0.857 |
| 7 | SRR11296846 | — | — | 0.855 |
| 8 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.852 |
| 9 | SRR975598 | — | — | 0.841 |
| 10 | 4EBF33F3-DA34-4866-81E5-F2D50A18D413 | — | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.460 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.340 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |